Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Axonics Inc (NQ: AXNX )

62.46 -0.20 (-0.32%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 27, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 260,581
Open 62.66
Bid (Size) 62.11 (1)
Ask (Size) 62.77 (1)
Prev. Close 62.66
Today's Range 61.57 - 63.00
52wk Range 38.41 - 79.92
Shares Outstanding 46,134,513
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Why Axonics Shares Are Trading Higher Today?
Axonics, Inc. (NASDAQ: AXNX) shares are trading higher after the company reported preliminary fourth-quarter and full-year 2022 total net revenue results above estimates. The company also issued FY23... 
Via Benzinga
Axonics Reports Preliminary Fiscal Year 2022 Revenue and Provides Fiscal Year 2023 Revenue Guidance
From Axonics, Inc.
Via Business Wire

Performance

YTD
+4.73%
+4.73%
1 Month
+1.51%
+1.51%
3 Month
-13.13%
-13.13%
6 Month
-3.72%
-3.72%
1 Year
+42.80%
+42.80%

More News

Read More
Analyst Ratings for Axonics
Via Benzinga
Axonics to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Axonics, Inc.
Via Business Wire
Axonics Receives Health Canada Approval for Fourth-Generation Rechargeable Sacral Neuromodulation System
From Axonics, Inc.
Via Business Wire
2 Fast-Growing Healthcare Stocks to Buy and Hold
Via The Motley Fool
Axonics Posts Smaller Than Expected Quarterly Loss, Raises Guidance
Via Benzinga
Axonics® to Participate in the Piper Sandler Healthcare Conference
From Axonics, Inc.
Via Business Wire
Axonics® Ranked No. 4 on the 2022 Deloitte Technology Fast 500™ List of the Fastest Growing Companies in North America
From Axonics, Inc.
Via Business Wire
Axonics® Reports Third Quarter 2022 Financial Results
From Axonics, Inc.
Via Business Wire
Analyst Ratings for Axonics
Via Benzinga
Axonics Risk/Reward Ratio Is Less Favorable, Analyst Says While Downgrading Stock
Via Benzinga
Where Axonics Stands With Analysts
Via Benzinga
Earnings Scheduled For October 31, 2022
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 21, 2022
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 10, 2022
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 12, 2022
Via Benzinga
Leading Medical Stocks, Including Sensus And Shockwave, Have Grown At Least 36% This Year
Via Investor's Business Daily
Piper Sandler Maintains Overweight Rating for Axonics: Here's What You Need To Know
Via Benzinga
Is This Medical Gear Maker Ready To Continue Its Rally?
Via MarketBeat
Topics Intellectual Property
Exposures Intellectual Property
Axonics® Announces First Patient Implants in Canada With New Recharge-Free Sacral Neuromodulation System
From Axonics, Inc.
Via Business Wire
Axonics® to Participate in September Investor Conferences
From Axonics, Inc.
Via Business Wire
Axonics® Expands Sacral Neuromodulation Intellectual Property Portfolio
From Axonics, Inc.
Via Business Wire
Axonics® Announces Closing of Public Stock Offering and Full Exercise of Underwriter’s Option to Purchase Additional Stock
From Axonics, Inc.
Via Business Wire
Axonics® Announces Pricing of Public Offering of Common Stock
From Axonics, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.